ZA201102763B - Ligands that have binding specificity for dc-sign - Google Patents

Ligands that have binding specificity for dc-sign

Info

Publication number
ZA201102763B
ZA201102763B ZA2011/02763A ZA201102763A ZA201102763B ZA 201102763 B ZA201102763 B ZA 201102763B ZA 2011/02763 A ZA2011/02763 A ZA 2011/02763A ZA 201102763 A ZA201102763 A ZA 201102763A ZA 201102763 B ZA201102763 B ZA 201102763B
Authority
ZA
South Africa
Prior art keywords
ligands
sign
binding specificity
specificity
binding
Prior art date
Application number
ZA2011/02763A
Other languages
English (en)
Inventor
Wildt Rudolf Maria De
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of ZA201102763B publication Critical patent/ZA201102763B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ZA2011/02763A 2008-10-21 2011-04-13 Ligands that have binding specificity for dc-sign ZA201102763B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21
PCT/EP2009/063655 WO2010046337A2 (en) 2008-10-21 2009-10-19 Ligands that have binding specificity for dc-sign

Publications (1)

Publication Number Publication Date
ZA201102763B true ZA201102763B (en) 2012-09-26

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/02763A ZA201102763B (en) 2008-10-21 2011-04-13 Ligands that have binding specificity for dc-sign

Country Status (16)

Country Link
US (1) US20110257373A1 (enExample)
EP (1) EP2356149A2 (enExample)
JP (1) JP2012506237A (enExample)
KR (1) KR20110071139A (enExample)
CN (1) CN102257009A (enExample)
AR (1) AR073905A1 (enExample)
AU (1) AU2009306424A1 (enExample)
BR (1) BRPI0919714A2 (enExample)
CA (1) CA2740856A1 (enExample)
EA (1) EA201100488A1 (enExample)
IL (1) IL212086A0 (enExample)
MX (1) MX2011004244A (enExample)
TW (1) TW201019962A (enExample)
UY (1) UY32189A (enExample)
WO (1) WO2010046337A2 (enExample)
ZA (1) ZA201102763B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004245A (es) * 2008-10-21 2011-09-06 Domantis Ltd Composicion para dirigirse a las celulas dendriticas.
US9481724B2 (en) * 2011-12-19 2016-11-01 The Rockefeller University hDC-sign binding peptides
WO2023028593A2 (en) * 2021-08-27 2023-03-02 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease
CN118184795B (zh) * 2022-12-13 2025-03-21 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用
CN120591214A (zh) * 2025-07-02 2025-09-05 山东第一医科大学第二附属医院 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598108A1 (en) * 1992-06-05 1994-05-25 Dade Produktions AG Rabbit single domain antibody and use thereof
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
JP4889493B2 (ja) * 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
JP5087274B2 (ja) * 2003-06-30 2012-12-05 ドマンティス リミテッド ポリペプチド
WO2005018610A1 (en) * 2003-08-21 2005-03-03 Lipotek Pty Ltd In vivo targeting of dendritic cells
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
JP5185624B2 (ja) * 2004-12-02 2013-04-17 ドマンティス リミテッド 血清アルブミンおよびｇｌｐ−１またはｐｙｙを標的とする二重特異性抗体
JP2008533115A (ja) * 2005-03-18 2008-08-21 ドマンティス リミテッド カンジダ抗原に対する抗体
EP1966242A1 (en) * 2005-12-06 2008-09-10 Domantis Limited Ligands that have binding specificity for egfr and/or vegf and methods of use therefor
US20100021473A1 (en) * 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
BRPI0710572A2 (pt) * 2006-01-24 2013-01-08 Domantis Limited ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
WO2008039432A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
EP2077863A4 (en) * 2006-10-31 2010-10-06 Domantis Ltd intrabodies
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Also Published As

Publication number Publication date
JP2012506237A (ja) 2012-03-15
CA2740856A1 (en) 2010-04-29
KR20110071139A (ko) 2011-06-28
UY32189A (es) 2010-05-31
EA201100488A1 (ru) 2011-12-30
AU2009306424A1 (en) 2010-04-29
MX2011004244A (es) 2011-05-25
US20110257373A1 (en) 2011-10-20
IL212086A0 (en) 2011-06-30
CN102257009A (zh) 2011-11-23
WO2010046337A3 (en) 2010-07-01
AR073905A1 (es) 2010-12-09
WO2010046337A2 (en) 2010-04-29
EP2356149A2 (en) 2011-08-17
BRPI0919714A2 (pt) 2015-12-08
TW201019962A (en) 2010-06-01

Similar Documents

Publication Publication Date Title
AP2012006188A0 (en) Bispecific binding molecules for anti-angiogenesistherapy.
IL212941A0 (en) Usirna complexes
GB0801161D0 (en) Catalysed filter
IL209664A0 (en) 5-substtuted isoindoline compounds
IL209727A0 (en) Pyridine compounds
EP2380639A4 (en) FIXING SNOWBOARD
IL219021A0 (en) Rsv specific binding molecule
GB0823686D0 (en) Holograms
IL214481A0 (en) Improved anti-serum albumin binding variants
EP2245153A4 (en) IMPROVED METHODS FOR PRODUCING SPECIFIC BINDING SAVINGS
IL214480A0 (en) Improved anti-serum albumin binding variants
IL212812A0 (en) Ligands that bind il-13
GB0906575D0 (en) Wire binding machines
EP2249646A4 (en) PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
IL212086A0 (en) Ligands that have binding specificity for dc-sign
IL207352A0 (en) Dual pharmacophores - pde4 - muscarinic antagonistics
SG2014010573A (en) ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION
GB0805688D0 (en) Enhancing signals
IL213675A0 (en) Chiral ligands
IL207351A0 (en) Dual pharmacophores - pde4 - muscarinic antagonistics
GB0713187D0 (en) biomolecule binding ligands
IL213445A0 (en) Anticancer compounds
IL207346A0 (en) Dual pharmacophores - pde4 - muscarinic antagonistics
EP2249830A4 (en) DUAL PHARMACOPHORES, ANTAGONISTS OF MUSCARINIC RECEPTORS AND INHIBITORS OF PDE4 ACTIVITY
GB0901231D0 (en) Ligands